BOSTON & LAKEWOOD, Colo.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and medical technology company Terumo Blood and Cell Technologies (Terumo BCT) announce a collaboration to enable on-line monitoring of critical process parameters in Terumo BCT’s Quantum Flex Cell Expansion System.

BOSTON＆LAKEWOOD，Colo。-908 Devices Inc.（纳斯达克股票代码：MASS），专门用于化学和生化分析的手持式和桌面设备的先驱，医疗技术公司Terumo血液和细胞技术（Terumo BCT）宣布合作，以便在Terumo BCT的Quantum Flex细胞扩增系统中实现对关键过程参数的在线监测。

The combination of the companies’ automation technologies will help advance the development of life-saving cell and gene therapies by providing insights into and control of one of the largest components of cell therapy development and manufacturing..

公司自动化技术的结合将有助于促进挽救生命的细胞和基因疗法的发展，为细胞疗法开发和制造的最大组成部分之一提供见解和控制。。

Cell and gene therapy developers are increasingly looking to automation to improve manufacturing efficiency, simplify workflows and reduce costs. But quality control today requires having expert staff spending hours on clean room floors to perform manual tasks without error or contamination instead of responding only as needed when issues arise..

细胞和基因治疗开发人员越来越希望自动化来提高制造效率，简化工作流程并降低成本。但是今天的质量控制要求专家工作人员在洁净室楼层花费数小时来执行手动任务而不会出错或污染，而不是仅在出现问题时根据需要做出响应。。

908 Devices is introducing MAVEN, its on-line glucose and lactate analyzer, to Terumo BCT’s Quantum Flex to provide cell and gene therapy development customers with the ability to monitor and control key process parameters in cell cultures without having to enter the clean room and perform manual sampling.

908设备正在将其在线葡萄糖和乳酸分析仪MAVEN推出Terumo BCT的Quantum Flex，为细胞和基因治疗开发客户提供监测和控制细胞培养中关键工艺参数的能力，而无需进入洁净室并执行手动采样。

This helps reduce the risk of contamination, save operator time and improve process understanding..

这有助于降低污染风险，节省操作员时间并提高流程理解。。

“We are proud to be working with a leading cell therapy technologies innovator to meet the next level of process integration in biopharma,” said Kevin J. Knopp, CEO and co-founder of 908 Devices. “We are committed to providing devices that enable scientists to gain insights that reduce costs and accelerate progress.”.

908设备首席执行官兼联合创始人Kevin J.Knopp说：“我们很自豪能够与领先的细胞治疗技术创新者合作，实现生物制药领域的下一级过程集成。”。“我们致力于提供使科学家能够获得降低成本和加速进展的见解的设备。”。

Terumo BCT’s Quantum Flex Cell Expansion System is an automated and functionally closed system purpose-built to meet the needs of cell therapy developers throughout their commercialization journey, from process development to clinical manufacturing. Quantum Flex helps lower the risk of contamination and enables reproducibility and process scale.

Terumo BCT的Quantum Flex细胞扩增系统是一款自动化和功能封闭的系统，专门用于满足细胞治疗开发人员从过程开发到临床制造的整个商业化过程中的需求。Quantum Flex有助于降低污染风险，并实现可重复性和工艺规模。

It is compatible with a range of suspension cells, adherent cells, viral vectors and exosomes..

它与一系列悬浮细胞，贴壁细胞，病毒载体和外泌体相容。。

“Combining our Quantum Flex platform with 908 Devices’ on-line monitoring will help cell therapy manufacturers reduce time-consuming manual steps that increase manufacturing costs and risks,” said Kathie Schneider, Director, Global Commercial Lead, Cell Therapy Technologies at Terumo BCT. “We continue to collaborate with industry experts to further enhance our solution offering to solve industry challenges.”.

Terumo BCT细胞治疗技术全球商业负责人Kathie Schneider说：“将我们的Quantum Flex平台与908设备的在线监控相结合，将有助于细胞治疗制造商减少耗时的手动步骤，从而提高制造成本和风险。”。“我们继续与行业专家合作，进一步加强我们的解决方案，以解决行业挑战。”。

About 908 Devices

大约908个设备

908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets.

908设备正在用其简单的手持和桌面设备彻底改变化学和生化分析，解决对生命应用至关重要的问题。该公司的设备用于询问未知和不可见的材料，并提供快速，可行的答案，以直接解决生命科学研究，生物加工，制药/生物制药，法医学和邻近市场中的一些最关键问题。

The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning..

该公司总部设在波士顿市中心，设计和制造创新产品，汇集质谱，微流体采样和分离，软件自动化和机器学习的力量。。

About Terumo Blood and Cell Technologies

关于Terumo血液和细胞技术

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions.

Terumo Blood and Cell Technologies是一家医疗技术公司。我们的产品，软件和服务使客户能够收集和准备血液和细胞，以帮助治疗具有挑战性的疾病和病症。

Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers, plasma collection facilities and private medical practices. Our customers are based in over 150 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending..

Terumo血液和细胞技术的客户包括血液中心，医院，治疗性单采血液成分诊所，细胞采集和处理组织，研究人员，血浆采集设施和私人医疗实践。我们的客户遍布全球150多个国家。我们拥有750多项专利，另有150多项正在申请中。。

We have global headquarters in Lakewood, Colo., U.S.A., along with five regional headquarters, eight manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology..

我们在美国科罗拉多州拉克伍德的全球总部以及全球五个区域总部，八个制造基地和六个创新发展中心。Terumo Blood and Cell Technologies是Terumo Corporation（TSE:4543）的子公司，Terumo Corporation是医疗技术的全球领导者。。

Forward-Looking Statements for 908 Devices

908设备的前瞻性声明

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products.

本新闻稿包括1995年“私人证券诉讼改革法”含义内的“前瞻性声明”。除历史事实陈述外的所有陈述均为前瞻性陈述，包括但不限于关于本公司产品的预期用途和能力的陈述。

Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov.

诸如“可能”，“将会”，“期望”，“计划”，“预期”，“估计”，“意图”之类的词语和类似的表达（以及引用未来事件，条件或情况的其他词语或表达）旨在识别前瞻性陈述。这些前瞻性声明基于管理层当前的预期，涉及已知和未知的风险，不确定性和假设，这些风险，不确定性和假设可能导致实际结果与任何前瞻性声明表达或暗示的任何结果大不相同，包括“风险因素”中概述的风险以及公司与证券交易委员会提交的文件中的其他地方，这些文件可在SEC的网站www.SEC.gov上找到。

Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results.

其他信息将在公司的年度和季度报告以及其与SEC不时提供的其他文件中提供。尽管公司认为其前瞻性报表中反映的预期是合理的，但不能保证未来的结果。

The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law..

本公司没有义务，也没有义务更新或修改本新闻稿中所作的任何前瞻性声明，以反映自本新闻稿发布之日起的变化，除非法律可能要求。。